The DOI matches its Crossref record; 204 of the 204 references it cites were found in a registry or an index.
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients’ advanced disease at diagnosis. The NCCN Guidelines for Pancreatic Adenocarcinoma provides recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pancreatic cancer. Although survival rates remain relatively unchanged, newer modalities of treatment, including targeted therapies, provide hope for improving patient outcomes. Sections of the manuscript have been updated to be concordant with the most recent update to the guidelines. This manuscript focuses on the available systemic therapy approaches, specifically the treatment options for locally advanced and metastatic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Self-citationMarabelle, A., Le, D. T., Ascierto, P. A., Di Giacomo, A. M., De Jesus-Acosta, A., Delord, J.-P., Geva, R., Gottfried, M., Penel, N., Hansen, A. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02105 · Cited by 3,048
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas
Tanaka, M., Fernández-del Castillo, C., Adsay, V., Chari, S., Falconi, M., Jang, J.-Y., Kimura, W., Levy, P., Pitman, M. B., Schmidt, C. M., et al. (2012) · Pancreatology · doi:10.1016/j.pan.2012.04.004 · Cited by 2,354
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas
Tanaka, M., Fernández-del Castillo, C., Kamisawa, T., Jang, J. Y., Levy, P., Ohtsuka, T., Salvia, R., Shimizu, Y., Tada, M., & Wolfgang, C. L. (2017) · Pancreatology · doi:10.1016/j.pan.2017.07.007 · Cited by 1,797
Oettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Pancreatitis and the Risk of Pancreatic Cancer
Lowenfels, A. B., Maisonneuve, P., Cavallini, G., Ammann, R. W., Lankisch, P. G., Andersen, J. R., Dimagno, E. P., Andren-Sandberg, A., & Domellof, L. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305203282001 · Cited by 1,757
Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation
Smith, B. D., Smith, G. L., Hurria, A., Hortobagyi, G. N., & Buchholz, T. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8983 · Cited by 1,721
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
Syngal, S., Brand, R. E., Church, J. M., Giardiello, F. M., Hampel, H. L., & Burt, R. W. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2014.435 · Cited by 1,662
A serine/threonine kinase gene defective in Peutz–Jeghers syndrome
Hemminki, A., Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A., Bignell, G., Warren, W., Aminoff, M., Höglund, P., et al. (1998) · Nature · doi:10.1038/34432 · Cited by 1,656
Cancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Very high risk of cancer in familial Peutz–Jeghers syndrome
Giardiello, F. M., Brensinger, J. D., Tersmette, A. C., Goodman, S. N., Petersen, G. M., Booker, S. V., Cruz–Correa, M., & Offerhaus, J. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.20228 · Cited by 1,445
Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer)
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., Nakagawa, H., Sotamaa, K., Prior, T. W., Westman, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043146 · Cited by 1,408
Alcohol consumption and site-specific cancer risk: a comprehensive dose–response meta-analysis
Bagnardi, V, Rota, M., Botteri, E., Tramacere, I., Islami, F., Fedirko, V, Scotti, L., Jenab, M., Turati, F., Pasquali, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.579 · Cited by 1,342
Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00986-1 · Cited by 1,222 · cited 2×
“Grade 3 or 4 adverse events that occurred most frequently with this regimen were neutropenia (27%), fatigue (14%), diarrhea (13%), and vomiting (11%).(205) Irinotecan liposomal injection, combined with 5-FU/leucovorin, was later approved by the FDA to be used as a subsequent treatment option after gemcitabinebased the…”
BackgroundMethodSelf-citationPeutz-Jeghers syndrome is caused by mutations in a novel serine threoninekinase
Jenne, D. E., Reomann, H., Nezu, J.-I., Friedel, W., Loff., S., Jeschke, R., Müller, O., Back, W., & Zimmer, M. (1998) · Nature Genetics · doi:10.1038/ng0198-38 · Cited by 1,205
Aaltonen, L. A., Salovaara, R., Kristo, P., Canzian, F., Hemminki, A., Peltomäki, P., Chadwick, R. B., Kääriäinen, H., Eskelinen, M., Järvinen, H., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382101 · Cited by 1,152
Von Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,044
Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30856-3 · Cited by 1,028
Hereditary Pancreatitis and the Risk of Pancreatic Cancer
Lowenfels, A. B., Maisonneuve, P., DiMagno, E. P., Elitsur, Y., Gates, L. K., Perrault, J., Whitcomb, D. C., & International Hereditary Pancreatitis Study Group (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.6.442 · Cited by 988
Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.023 · Cited by 950
Suker, M., Beumer, B. R., Sadot, E., Marthey, L., Faris, J. E., Mellon, E. A., El-Rayes, B. F., Wang-Gillam, A., Lacy, J., Hosein, P. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00172-8 · Cited by 939
Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer
Hampel, H., Frankel, W. L., Martin, E., Arnold, M., Khanduja, K., Kuebler, P., Clendenning, M., Sotamaa, K., Prior, T., Westman, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5950 · Cited by 876
Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M. F., O'Reilly, E., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 845
Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., Harper, P. G., Dunn, J., Tudur-Smith, C., West, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2446 · Cited by 823
Epidemiology of pancreatic cancer: an overview
Raimondi, S., Maisonneuve, P., & Lowenfels, A. B. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.177 · Cited by 740
Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 729
Self-citationCancers with increasing incidence trends in the United States: 1999 through 2008
Simard, E. P., Ward, E. M., Siegel, R., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20141 · Cited by 724
Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schönekäs, H., Rost, A., Neuhaus, H., Haag, C., Clemens, M., Heinrich, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.1490 · Cited by 683
Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds
Klein, A. P., Brune, K. A., Petersen, G. M., Goggins, M., Tersmette, A. C., Offerhaus, G. J. A., Griffin, C., Cameron, J. L., Yeo, C. J., Kern, S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3823 · Cited by 678
Goldstein, D., El-Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., Scheithauer, W., Siena, S., Tabernero, J., Teixeira, L., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju413 · Cited by 658
Van Cutsem, E., Vervenne, W. L., Bennouna, J., Humblet, Y., Gill, S., Van Laethem, J.-L., Verslype, C., Scheithauer, W., Shang, A., Cosaert, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0238 · Cited by 650
Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 632
Buccheri, G., Ferrigno, D., & Tamburini, M. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00664-8 · Cited by 629
Clinical and genetic characteristics of hereditary pancreatitis in Europe
Howes, N., Lerch, M. M., Greenhalf, W., Stocken, D. D., Ellis, I., Simon, P., Truninger, K., Ammann, R., Cavallini, G., Charnley, R. M., et al. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00013-8 · Cited by 623
Probability of Pancreatic Cancer Following Diabetes: A Population-Based Study
Chari, S. T., Leibson, C. L., Rabe, K. G., Ransom, J., de Andrade, M., & Petersen, G. M. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.05.007 · Cited by 603
Mackey, J. R., Mani, R. S., Selner, M., Mowles, D., YOUNG, J., Belt, J. A., Crawford, C. R., & Cass, C. E. (1998) · PubMed · Cited by 599
Herrmann, R., Bodoky, G., Ruhstaller, T., Glimelius, B., Bajetta, E., Schüller, J., Saletti, P., Bauer, J., Figer, A., Pestalozzi, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0886 · Cited by 595
Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruia, G., & Miller, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.082 · Cited by 588
Antidiabetic Therapies Affect Risk of Pancreatic Cancer
Li, D., Yeung, S. J., Hassan, M. M., Konopleva, M., & Abbruzzese, J. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.013 · Cited by 584
PD-1 blockade in tumors with mismatch repair deficiency.
Le, D. T., Uram, J. N., Wang, H., Bartlett, B., Kemberling, H., Eyring, A., Skora, A., Azad, N. S., Laheru, D. A., Donehower, R. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.lba100 · Cited by 565
Risk of Pancreatic Cancer in Families With Lynch Syndrome
Kastrinos, F. (2009) · JAMA · doi:10.1001/jama.2009.1529 · Cited by 544
High Cancer Risk in Peutz–Jeghers Syndrome: A Systematic Review and Surveillance Recommendations
van Lier, M. G. F., Wagner, A., Mathus-Vliegen, E. M. H., Kuipers, E. J., Steyerberg, E. W., & van Leerdam, M. E. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.725 · Cited by 542
Tempero, M., Plunkett, W., Ruiz van Haperen, V., Hainsworth, J., Hochster, H., Lenzi, R., & Abbruzzese, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.140 · Cited by 519
Self-citationGourgou-Bourgade, S., Bascoul-Mollevi, C., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.4869 · Cited by 501
European experts consensus statement on cystic tumours of the pancreas
Del Chiaro, M., Verbeke, C., Salvia, R., Klöppel, G., Werner, J., McKay, C., Friess, H., Manfredi, R., Van Cutsem, E., Löhr, M., et al. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.01.010 · Cited by 498
ATM Mutations in Patients with Hereditary Pancreatic Cancer
Roberts, N. J., Jiao, Y., Yu, J., Kopelovich, L., Petersen, G. M., Bondy, M. L., Gallinger, S., Schwartz, A. G., Syngal, S., Cote, M. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0194 · Cited by 491 · cited 1×
“Whole-genome sequencing allowed for the identification of germline mutations in ATM, a DNA damage response gene, in 2 kindreds with familial pancreatic cancer.(108) Further NCCN GUIDELINES Pancreatic Adenocarcinoma, Version 2.”
BackgroundOettle, H., Riess, H., Stieler, J. M., Heil, G., Schwaner, I., Seraphin, J., Görner, M., Mölle, M., Greten, T. F., Lakner, V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6995 · Cited by 487
BRCA2 germline mutations in familial pancreatic carcinoma
Hahn, S. A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Korte, B., Gerdes, B., Kress, R., Ziegler, A., Raeburn, J. A., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.3.214 · Cited by 480
Body Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer
Li, D. (2009) · JAMA · doi:10.1001/jama.2009.886 · Cited by 469
Farrell, J. J., Elsaleh, H., Garcia, M., Lai, R., Ammar, A., Regine, W. F., Abrams, R., Benson, A. B., Macdonald, J., Cass, C. E., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2008.09.067 · Cited by 458
Self-citationEheman, C., Henley, S. J., Ballard‐Barbash, R., Jacobs, E. J., Schymura, M. J., Noone, A., Pan, L., Anderson, R. N., Fulton, J. E., Kohler, B. A., et al. (2012) · Cancer · doi:10.1002/cncr.27514 · Cited by 457
Risk of pancreatic adenocarcinoma in chronic pancreatitis
Malka, D., Hammel, P., Maire, F., Rufat, P., Madeira, I., Pessione, F., Lévy, P., & Ruszniewski, P. (2002) · Gut · doi:10.1136/gut.51.6.849 · Cited by 457
Poplin, E., Feng, Y., Berlin, J., Rothenberg, M. L., Hochster, H., Mitchell, E., Alberts, S., O'Dwyer, P., Haller, D., Catalano, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9007 · Cited by 438
Self-citationOverall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
Golan, T., Kanji, Z. S., Epelbaum, R., Devaud, N., Dagan, E., Holter, S., Aderka, D., Paluch-Shimon, S., Kaufman, B., Gershoni-Baruch, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.418 · Cited by 436
Heinemann, V., Boeck, S., Hinke, A., Labianca, R., & Louvet, C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-82 · Cited by 434
Metformin Therapy and Risk of Cancer in Patients with Type 2 Diabetes: Systematic Review
Franciosi, M., Lucisano, G., Lapice, E., Strippoli, G. F. M., Pellegrini, F., & Nicolucci, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071583 · Cited by 428
Cancer risks in BRCA2 families: estimates for sites other than breast and ovary
van Asperen, C. J., Brohet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., Verhoef, S., Vasen, H. F. A., Ausems, M. G. E. M., Menko, F. H., Gomez Garcia, E. B., Klijn, J. G. M., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.028829 · Cited by 420
Su, G. H., Hruban, R. H., Bansal, R. K., Bova, G. S., Tang, D. J., Shekher, M. C., Westerman, A. M., Entius, M. M., Goggins, M., Yeo, C. J., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65440-5 · Cited by 417
Bosetti, C., Lucenteforte, E., Silverman, D. T., Petersen, G., Bracci, P. M., Ji, B. T., Negri, E., Li, D., Risch, H. A., Olson, S. H., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr541 · Cited by 411
Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature
Liede, A., Karlan, B. Y., & Narod, S. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.055 · Cited by 407
Kindler, H. L., Ioka, T., Richel, D. J., Bennouna, J., Létourneau, R., Okusaka, T., Funakoshi, A., Furuse, J., Park, Y. S., Ohkawa, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70004-3 · Cited by 403
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7401 · Cited by 398
Colucci, G., Giuliani, F., Gebbia, V., Biglietto, M., Rabitti, P., Uomo, G., Cigolari, S., Testa, A., Maiello, E., & Lopez, M. (2002) · PubMed · Cited by 384
Lynch, S. M., Vrieling, A., Lubin, J. H., Kraft, P., Mendelsohn, J. B., Hartge, P., Canzian, F., Steplowski, E., Arslan, A. A., Gross, M., et al. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp134 · Cited by 372
Pelzer, U., Schwaner, I., Stieler, J., Adler, M., Seraphin, J., Dörken, B., Riess, H., & Oettle, H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.011 · Cited by 370
Diabetes and the Risk of Pancreatic Cancer
Gullo, L., Pezzilli, R., & Morselli-Labate, A. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199407143310203 · Cited by 367
Vasen, H. F. A., Gruis, N. A., Frants, R. R., van der Velden, P. A., Hille, E. T. M., & Bergman, W. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000915)87:6<809::aid-ijc8>3.0.co;2-u · Cited by 347
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., Garner, E., Campbell, F., Mackey, J. R., Costello, E., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djt347 · Cited by 337
New insights into pancreatic cancer-induced paraneoplastic diabetes
Sah, R. P., Nagpal, S. J. S., Mukhopadhyay, D., & Chari, S. T. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.49 · Cited by 334
Win, A. K., Young, J. P., Lindor, N. M., Tucker, K. M., Ahnen, D. J., Young, G. P., Buchanan, D. D., Clendenning, M., Giles, G. G., Winship, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5590 · Cited by 333
Risk Factors for Pancreatic Cancer: Case-Control Study
Hassan, M. M., Bondy, M. L., Wolff, R. A., Abbruzzese, J. L., Vauthey, J.-N., Pisters, P. W., Evans, D. B., Khan, R., Chou, T.-H., Lenzi, R., et al. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01510.x · Cited by 331
Self-citationBody mass index and pancreatic cancer risk: A meta‐analysis of prospective studies
Larsson, S. C., Orsini, N., & Wolk, A. (2007) · International Journal of Cancer · doi:10.1002/ijc.22535 · Cited by 320
Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Sadeghi, N., Abbruzzese, J. L., Yeung, S.-C. J., Hassan, M., & Li, D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2994 · Cited by 305
Colucci, G., Labianca, R., Di Costanzo, F., Gebbia, V., Cartenì, G., Massidda, B., Dapretto, E., Manzione, L., Piazza, E., Sannicolò, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4433 · Cited by 304
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
Zhen, D. B., Rabe, K. G., Gallinger, S., Syngal, S., Schwartz, A. G., Goggins, M. G., Hruban, R. H., Cote, M. L., McWilliams, R. R., Roberts, N. J., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.153 · Cited by 295
Gill, S., Ko, Y.-J., Cripps, C., Beaudoin, A., Dhesy-Thind, S., Zulfiqar, M., Zalewski, P., Do, T., Cano, P., Lam, W. Y. H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.5776 · Cited by 288
Obesity, Recreational Physical Activity, and Risk of Pancreatic Cancer In a Large U.S. Cohort
Patel, A. V., Rodriguez, C., Bernstein, L., Chao, A., Thun, M. J., & Calle, E. E. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0583 · Cited by 286
Larsson, S. C., & Wolk, A. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.585 · Cited by 281
Whelan, A. J., Bartsch, D., & Goodfellow, P. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510123331505 · Cited by 280
PALB2 mutations in European familial pancreatic cancer families
Slater, E., Langer, P., Niemczyk, E., Strauch, K., Butler, J., Habbe, N., Neoptolemos, J., Greenhalf, W., & Bartsch, D. (2010) · Clinical Genetics · doi:10.1111/j.1399-0004.2010.01425.x · Cited by 278
Reni, M., Cordio, S., Milandri, C., Passoni, P., Bonetto, E., Oliani, C., Luppi, G., Nicoletti, R., Galli, L., Bordonaro, R., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70175-3 · Cited by 277
Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
Soranna, D., Scotti, L., Zambon, A., Bosetti, C., Grassi, G., Catapano, A., La Vecchia, C., Mancia, G., & Corrao, G. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0462 · Cited by 274
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02770 · Cited by 270
Self-citationUpdate on Familial Pancreatic Cancer
Hruban, R. H., Canto, M. I., Goggins, M., Schulick, R., & Klein, A. P. (2010) · Advances in Surgery · doi:10.1016/j.yasu.2010.05.011 · Cited by 268
Fanconi anemia gene mutations in young-onset pancreatic cancer.
van der Heijden, M. S., Yeo, C. J., Hruban, R. H., & Kern, S. E. (2003) · PubMed · Cited by 264
Duell, E. J., Lucenteforte, E., Olson, S. H., Bracci, P. M., Li, D., Risch, H. A., Silverman, D. T., Ji, B. T., Gallinger, S., Holly, E. A., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds140 · Cited by 263
Importance of Age of Onset in Pancreatic Cancer Kindreds
Brune, K. A., Lau, B., Palmisano, E., Canto, M., Goggins, M. G., Hruban, R. H., & Klein, A. P. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp466 · Cited by 257
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
T. H. B. C. S. G., Iqbal, J., Ragone, A., Lubinski, J., Lynch, H. T., Moller, P., Ghadirian, P., Foulkes, W. D., Armel, S., Eisen, A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.483 · Cited by 252
Releasing the Brakes on Cancer Immunotherapy
Ribas, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1510079 · Cited by 252
Lowery, M. A., Kelsen, D. P., Stadler, Z. K., Yu, K. H., Janjigian, Y. Y., Ludwig, E., D'Adamo, D. R., Salo-Mullen, E., Robson, M. E., Allen, P. J., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0185 · Cited by 245
Grunewald, R., Abbruzzese, J. L., Tarassoff, P., & Plunkett, W. (1991) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685109 · Cited by 244
Maréchal, R., Bachet, J., Mackey, J. R., Dalban, C., Demetter, P., Graham, K., Couvelard, A., Svrcek, M., Bardier–Dupas, A., Hammel, P., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.006 · Cited by 241
Familial pancreatic cancer: a review.
Lynch, H. T., Smyrk, T. C., Kern, S. E., Hruban, R. H., Lightdale, C. J., Lemon, S. J., Lynch, J. F., Fusaro, L., Fusaro, R. M., & Ghadirian, P. (1996) · PubMed · Cited by 239
Lucenteforte, E., La Vecchia, C., Silverman, D., Petersen, G. M., Bracci, P. M., Ji, B. T., Bosetti, C., Li, D., Gallinger, S., Miller, A. B., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr120 · Cited by 238
Conroy, T., Paillot, B., François, E., Bugat, R., Jacob, J.-H., Stein, U., Nasca, S., Metges, J.-P., Rixe, O., Michel, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.050 · Cited by 237
Prediabetes and the risk of cancer: a meta-analysis
Huang, Y., Cai, X., Qiu, M., Chen, P., Tang, H., Hu, Y., & Huang, Y. (2014) · Diabetologia · doi:10.1007/s00125-014-3361-2 · Cited by 234
Pancreatic Cystic Neoplasms: Management and Unanswered Questions
Farrell, J. J., & Fernández-del Castillo, C. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.073 · Cited by 225
Gonçalves, A., Gilabert, M., François, E., Dahan, L., Perrier, H., Lamy, R., Re, D., Largillier, R., Gasmi, M., Tchiknavorian, X., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds135 · Cited by 225
Lynch, H. T., Brand, R. E., Hogg, D., Deters, C. A., Fusaro, R. M., Lynch, J. F., Liu, L., Knezetic, J., Lassam, N. J., Goggins, M., et al. (2002) · Cancer · doi:10.1002/cncr.10159 · Cited by 222
PancPRO: Risk Assessment for Individuals With a Family History of Pancreatic Cancer
Wang, W., Chen, S., Brune, K. A., Hruban, R. H., Parmigiani, G., & Klein, A. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2452 · Cited by 219
Stein, S. M., James, E. S., Deng, Y., Cong, X., Kortmansky, J. S., Li, J., Staugaard, C., Indukala, D., Boustani, A. M., Patel, V., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.45 · Cited by 209
BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
Ferrone, C. R., Levine, D. A., Tang, L. H., Allen, P. J., Jarnagin, W., Brennan, M. F., Offit, K., & Robson, M. E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5546 · Cited by 206
Self-citationPhase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer
Cartwright, T. H., Cohn, A. L., Varkey, J. A., Chen, Y.-M., Szatrowski, T. P., Cox, J. V., & Schulz, J. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.160 · Cited by 201
Stathopoulos, G. P., Syrigos, K., Aravantinos, G., Polyzos, A., Papakotoulas, P., Fountzilas, G., Potamianou, A., Ziras, N., Boukovinas, J., Varthalitis, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603301 · Cited by 198
International consensus guidelines for the management of IPMN and MCN of the pancreas.
Tanaka, M. (2007) · PubMed · Cited by 198
Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis
Maisonneuve, P., Amar, S., & Lowenfels, A. B. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx019 · Cited by 196
de Snoo, F. A., Bishop, D. T., Bergman, W., van Leeuwen, I., van der Drift, C., van Nieuwpoort, F. A., Out-Luiting, C. J., Vasen, H. F., ter Huurne, J. A. C., Frants, R. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0403 · Cited by 181
Wang, Z., Lai, S.-T., Xie, L., Zhao, J.-D., Ma, N.-Y., Zhu, J., Ren, Z.-G., & Jiang, G.-L. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.007 · Cited by 176
Chung, V., McDonough, S., Philip, P. A., Cardin, D., Wang-Gillam, A., Hui, L., Tejani, M. A., Seery, T. E., Dy, I. A., Al Baghdadi, T., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5383 · Cited by 176 · cited 1×
“7 months, which is comparable to the median OS rates found in the CONKO-003 and PANCREOX trials.(204) In the NAPOLI-1 phase III randomized trial, the effects of nanoliposomal irinotecan were examined in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy.”
ResultSelf-citationAlsamarrai, A., Das, S. L. M., Windsor, J. A., & Petrov, M. S. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.038 · Cited by 174
Yoo, C., Hwang, J. Y., Kim, J.-E., Kim, T. W., Lee, J. S., Park, D. H., Lee, S. S., Seo, D. W., Lee, S. K., Kim, M.-H., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605374 · Cited by 170
Vrieling, A., Bueno‐de‐Mesquita, H. B., Boshuizen, H. C., Michaud, D. S., Severinsen, M. T., Overvad, K., Olsen, A., Tjønneland, A., Clavel‐Chapelon, F., Boutron‐Ruault, M., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.24907 · Cited by 169
Liao, W.-C., Tu, Y.-K., Wu, M.-S., Lin, J.-T., Wang, H.-P., & Chien, K.-L. (2015) · BMJ · doi:10.1136/bmj.g7371 · Cited by 167
Releasing the Brakes on Cancer Immunotherapy
Littman, D. R. (2015) · Cell · doi:10.1016/j.cell.2015.08.038 · Cited by 166
FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma
Sadot, E., Doussot, A., O’Reilly, E. M., Lowery, M. A., Goodman, K. A., Do, R. K. G., Tang, L. H., Gönen, M., D’Angelica, M. I., DeMatteo, R. P., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4647-4 · Cited by 161
Genkinger, J. M., Kitahara, C. M., Bernstein, L., Berrington de Gonzalez, A., Brotzman, M., Elena, J. W., Giles, G. G., Hartge, P., Singh, P. N., Stolzenberg-Solomon, R. Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv355 · Cited by 159
Self-citationInterconversion of three measures of performance status: An empirical analysis
Ma, C., Bandukwala, S., Burman, D., Bryson, J., Seccareccia, D., Banerjee, S., Myers, J., Rodin, G., Dudgeon, D., & Zimmermann, C. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.06.126 · Cited by 158
Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes
Visser, B. C., Ma, Y., Zak, Y., Poultsides, G. A., Norton, J. A., & Rhoads, K. F. (2012) · HPB · doi:10.1111/j.1477-2574.2012.00496.x · Cited by 154
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., et al. (2015) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 154
Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer
Antwi, S. O., Eckert, E. C., Sabaque, C., Leof, E. R., Hawthorne, K. M., Bamlet, W. R., Rabe, K. G., Oberg, A. L., & Petersen, G. M. (2015) · Cancer Causes & Control · doi:10.1007/s10552-015-0652-y · Cited by 152
Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case–Control Analysis
Bodmer, M., Becker, C., Meier, C., Jick, S. S., & Meier, C. R. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.483 · Cited by 152
Genomic profiling of breast tumours in relation to BRCAabnormalities and phenotypes
Stefánsson, Ó. A., Jonasson, J. G., Jóhannsson, Ó. Þ., Ólafsdóttir, K., Steinarsdóttir, M., Valgeirsdóttir, S., & Eyfjord, J. E. (2009) · Breast Cancer Research · doi:10.1186/bcr2334 · Cited by 152
Germ Line Fanconi Anemia Complementation Group C Mutations and Pancreatic Cancer
Couch, F. J., Johnson, M. R., Rabe, K. G., Boardman, L., McWilliams, R. R., de Andrade, M., & Petersen, G. M. (2005) · Cancer Research · doi:10.1158/0008-5472.383.65.2 · Cited by 146
Dietary Fatty Acids and Pancreatic Cancer in the NIH-AARP Diet and Health Study
Thiébaut, A. C. M., Jiao, L., Silverman, D. T., Cross, A. J., Thompson, F. E., Subar, A. F., Hollenbeck, A. R., Schatzkin, A. G., & Stolzenberg‐Solomon, R. Z. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp168 · Cited by 146
Xiong, H. Q., Varadhachary, G. R., Blais, J. C., Hess, K. R., Abbruzzese, J. L., & Wolff, R. A. (2008) · Cancer · doi:10.1002/cncr.23810 · Cited by 143
Self-citationTabernero, J. M., Chiorean, E. G., Infante, J. R., Hingorani, S. R., Ganju, V., Weekes, C. D., Scheithauer, W., Ramanathan, R. K., Goldstein, D., Penenberg, D. N., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0394 · Cited by 142
Self-citationRahma, O. E., Duffy, A. G., Liewehr, D. J., Steinberg, S. M., & Greten, T. F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt166 · Cited by 140
Demols, A., Peeters, M., Polus, M., Maréchal, R., Gay, F., Monsaert, E., Hendlisz, A., & Laethem, J. V. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602966 · Cited by 138
Heinemann, V., Labianca, R., Hinke, A., & Louvet, C. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm283 · Cited by 138
Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients
Hu, C., Hart, S. N., Bamlet, W. R., Moore, R. M., Nandakumar, K., Eckloff, B. W., Lee, Y. K., Petersen, G. M., McWilliams, R. R., & Couch, F. J. (2016) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0455 · Cited by 137
Elena, J. W., Steplowski, E., Yu, K. F., Hartge, P. A., Tobias, G. S., Brotzman, M. J., Chanock, S. J., Stolzenberg‐Solomon, R. Z., Arslan, A. A., Bueno-de-Mesquita, H. B., et al. (2012) · Cancer Causes & Control · doi:10.1007/s10552-012-0078-8 · Cited by 137
Self-citationNew-Onset Diabetes and Pancreatic Cancer
Gupta, S. N., Vittinghoff, E., Bertenthal, D., Corley, D. A., Shen, H., Walter, L. C., & McQuaid, K. R. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.06.024 · Cited by 137
Maisey, N. R., Chau, I., Cunningham, D., Norman, A. R., Seymour, M., Hickish, T., Iveson, T. J., O'Brien, M. E. R., Tebbutt, N. C., Harrington, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.029 · Cited by 136
Korsse, S. E., Harinck, F., van Lier, M. G., Biermann, K., Offerhaus, G. J. A., Krak, N. C., Looman, C. W. N., van Veelen, W., Kuipers, E. J., Wagner, A., et al. (2012) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101277 · Cited by 135
Singh, S., Singh, P. P., Singh, A. G., Murad, M. H., McWilliams, R. R., & Chari, S. T. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.7 · Cited by 127
Are Racial Disparities in Pancreatic Cancer Explained by Smoking and Overweight/Obesity?
Arnold, L. D., Patel, A. V., Yan, Y., Jacobs, E. J., Thun, M. J., Calle, E. E., & Colditz, G. A. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0080 · Cited by 127
Pelzer, U., Kubica, K., Stieler, J., Schwaner, I., Heil, G., Görner, M., Mölle, M., Hilbig, A., Dörken, B., Riess, H. B., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4508 · Cited by 127
Ciliberto, D., Botta, C., Correale, P., Rossi, M., Caraglia, M., Tassone, P., & Tagliaferri, P. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.019 · Cited by 125
Heinemann, V., Vehling‐Kaiser, U., Waldschmidt, D., Kettner, E., Märten, A., Winkelmann, C., Klein, S., Kojouharoff, G., Gauler, T. C., von Weikersthal, L. F., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302759 · Cited by 124
Increased Risk of Pancreatic Adenocarcinoma After Acute Pancreatitis
Munigala, S., Kanwal, F., Xian, H., Scherrer, J. F., & Agarwal, B. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.12.033 · Cited by 121
Ychou, M., Conroy, T., Seitz, J., Gourgou, S., Hua, A., Méry-Mignard, D., & Kramar, A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg119 · Cited by 118
Song, S., Wang, B., Zhang, X., Hao, L., Hu, X., Li, Z., & Sun, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134321 · Cited by 117
[A serine/threonine kinase gene defective in Peutz-Jeghers syndrome].
Hemminki, A., Avizienyte, E., Roth, S., Loukola, A., Aaltonen, L. A., Järvinen, H., & de la Chapelle, A. (1998) · PubMed · Cited by 116
Plasma 25-Hydroxyvitamin D and Risk of Pancreatic Cancer
Wolpin, B. M., Ng, K., Bao, Y., Kraft, P. L., Stampfer, M. J., Michaud, D. S., Ma, J., Buring, J. E., Sesso, H. D., Lee, I.-M. M., et al. (2012) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0836 · Cited by 114
Self-citationAn overview of hereditary pancreatitis
Rebours, V., Lévy, P., & Ruszniewski, P. B. (2011) · Digestive and Liver Disease · doi:10.1016/j.dld.2011.08.003 · Cited by 110
Chiorean, E. G., Hoff, D. D. V., Reni, M., Arena, F. P., Infante, J. R., Bathini, V., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw006 · Cited by 109
Self-citationCohort study of workers exposed to betanaphthylamine and benzidine.
Mancuso, T. F., & EL-ATTAR, A. A. (1967) · PubMed · Cited by 109
Physical activity and risk of pancreatic cancer: a systematic review and meta-analysis
Behrens, G., Jochem, C., Schmid, D., Keimling, M., Ricci, C., & Leitzmann, M. F. (2015) · European Journal of Epidemiology · doi:10.1007/s10654-015-0014-9 · Cited by 107
Fine, R. L., Fogelman, D. R., Schreibman, S. M., Desai, M., Sherman, W. H., Strauss, J. B., Guba, S. C., Andrade, R., & Chabot, J. A. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0473-0 · Cited by 100
Chiorean, E. G., Hoff, D. D. V., Tabernero, J. M., El-Maraghi, R. H., Ma, W. W., Reni, M., Harris, M., Whorf, R. C., Liu, H. W., Li, J. S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.185 · Cited by 91
Self-citationPancreatic cancer risk in hereditary pancreatitis
Weiß, F. U. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00070 · Cited by 90
Zaniboni, A., Aitini, E., Barni, S., Ferrari, D., Cascinu, S., Catalano, V., Valmadre, G., Ferrara, D., Veltri, E. M., Codignola, C., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1875-1 · Cited by 90
Peixoto, R. D., Ho, M., Renouf, D. J., Lim, H. J., Gill, S., Ruan, J. Y., & Cheung, W. Y. (2015) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000193 · Cited by 88
Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
Sun, C., Ansari, D., Andersson, R., & Wu, D.-Q. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i35.4944 · Cited by 87
Kulke, M. H., Tempero, M. A., Niedzwiecki, D., Hollis, D. R., Kindler, H. L., Cusnir, M., Enzinger, P. C., Gorsch, S. M., Goldberg, R. M., & Mayer, R. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1309 · Cited by 86
Self-citationWorni, M., Güller, U., White, R. R., Castleberry, A. W., Pietrobon, R. S., Cerny, T., Gloor, B., & Koeberle, D. (2013) · Pancreas · doi:10.1097/mpa.0b013e318291fbc5 · Cited by 84
Rohrmann, S., Linseisen, J., Nöthlings, U., Overvad, K., Egeberg, R., Tjønneland, A. M., Boutron‐Ruault, M., Clavel‐Chapelon, F., Cottet, V., Pala, V. M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27637 · Cited by 83
Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson
Chaiteerakij, R., Petersen, G. M., Bamlet, W. R., Rabe, K. G., Zhen, D. B., Burch, P. A., Leof, E. R., Roberts, L. R., & Oberg, A. L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3511 · Cited by 83
Pancreatic Cancer Clinical Trials and Accrual in the United States
Hoos, W. A., James, P. M., Rahib, L., Talley, A. W., Fleshman, J. M., & Matrisian, L. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4823 · Cited by 74
Raghavan, S., Ballehaninna, U. K., & Chamberlain, R. S. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182a6db8e · Cited by 74
Majdak, E., Dębniak, J., Milczek, T., Cornelisse, C. J., Devilee, P., Emerich, J., Jassem, J., & de Bock, G. H. (2005) · Cancer · doi:10.1002/cncr.21276 · Cited by 74
Anderson, M. A., Zolotarevsky, E., Cooper, K. L., Sherman, S., Shats, O., Whitcomb, D. C., Lynch, H. T., Ghiorzo, P., Rubinstein, W. S., Vogel, K. J., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.288 · Cited by 73
Demetri, G. D., Paz-Ares, L. G., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Kim, E. S., Blakely, C. M., Krauss, J. C., Sigal, D. S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.017 · Cited by 71
Clinical and pathologic features of familial pancreatic cancer
Humphris, J. L., Johns, A. L., Simpson, S. H., Cowley, M. J., Pajic, M., Chang, D. K.-F., Nagrial, A. M., Chin, V. T., Chantrill, L. A., Pinese, M., et al. (2014) · Cancer · doi:10.1002/cncr.28863 · Cited by 69
Lucas, A. L., Frado, L. E., Hwang, C., Kumar, S., Khanna, L. G., Levinson, E. J., Chabot, J. A., Chung, W. K., & Frucht, H. (2014) · Cancer · doi:10.1002/cncr.28662 · Cited by 68
Pancreatitis and pancreatic cancer in two large pooled case–control studies
Bracci, P. M., Wang, F., Hassan, M. M., Gupta, S. N., Li, D., & Holly, E. A. (2009) · Cancer Causes & Control · doi:10.1007/s10552-009-9424-x · Cited by 68
Germline BRCA1 mutations predispose to pancreatic adenocarcinoma
Al-Sukhni, W., Rothenmund, H., Borgida, A., Zogopoulos, G., O’Shea, A.-M., Pollett, A. F., & Gallinger, S. (2008) · Human Genetics · doi:10.1007/s00439-008-0554-0 · Cited by 67
Dairy products and pancreatic cancer risk: a pooled analysis of 14 cohort studies
Genkinger, J. M., Wang, M., Li, R., Albanes, D., Anderson, K. E., Bernstein, L., van den Brandt, P. A., English, D. R., Freudenheim, J. L., Fuchs, C. S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu019 · Cited by 66
Rainone, M., Singh, I., Salo‐Mullen, E. E., Stadler, Z. K., & O'Reilly, E. M. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5963 · Cited by 64
Diabetes and pancreatic cancer survival: a prospective cohort-based study
Toriola, A. T., Stolzenberg‐Solomon, R. Z., Dalidowitz, L., Linehan, D. C., & Colditz, G. A. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.224 · Cited by 60
Li, Q., Yan, H., Liu, W., Zhen, H., Yang, Y., & Cao, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104346 · Cited by 59
Goldstein, D., Hoff, D. D. V., Moore, M. J., Greeno, E. W., Tortora, G., Ramanathan, R. K., Macarulla, T. M., Liu, H. W., Pilot, R., Ferrara, S., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.10.017 · Cited by 56
Sinn, M., Riess, H. B., Sinn, B. V., Stieler, J., Pelzer, U., Striefler, J. K., Oettle, H., Bahra, M., Denkert, C., Bläker, H., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.005 · Cited by 51
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts
Neuzillet, C. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i33.4533 · Cited by 51
Aranda, E., Manzano, J. L., Rivera, F., Galán, M., Valladares‐Ayerbes, M., Pericay, C., Safont, M. J., Mendez, M. J., Irigoyen, A., Arrivi, A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr560 · Cited by 51
Jesus‐Acosta, A. D., Oliver, G. R., Blackford, A. L., Kinsman, K., Flores, E. I., Wilfong, L. S., Zheng, L., Donehower, R. C., Cosgrove, D., Laheru, D. A., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1704-y · Cited by 46
Waterhouse, M. A., Risch, H. A., Bosetti, C., Anderson, K. E., Petersen, G. M., Bamlet, W. R., Cotterchio, M., Cleary, S. P., Ibiebele, T. I., Vecchia, C. L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv236 · Cited by 44
New-onset Diabetes Patients Need Pancreatic Cancer Screening?
Lee, J. H., Kim, S., Park, H. Y., Lee, K. H., Lee, K. T., Lee, J. K., Bae, J. C., & Kim, K. W. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318238348c · Cited by 43
Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer
Saif, M. W., Lee, Y., & Kim, R. D. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012453755 · Cited by 38
Ormanns, S., Heinemann, V., Raponi, M., Isaacson, J. D., Laubender, R. P., Haas, M., Krüger, S., Kleespies, A., Mann, E., Bartosiewicz, M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.023 · Cited by 36
Boeck, S. H., Vehling‐Kaiser, U., Waldschmidt, D., Kettner, E., Märten, A., Winkelmann, C., Klein, S., Kojouharoff, G., Gauler, T. C., von Weikersthal, L. F., et al. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32833123ed · Cited by 34
(2012) · Annals of Oncology · doi:10.1093/annonc/mds491 · Cited by 34
Yamaue, H., Shimizu, A., Hagiwara, Y., Sho, M., Yanagimoto, H., Nakamori, S., Ueno, H., Ishii, H., Kitano, M., Sugimori, K., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3250-8 · Cited by 29
Lee, H. S., Chung, M. J., Park, J. Y., Bang, S., Park, S. W., Kim, H. G., Noh, M. H., Lee, S. H., Kim, Y., Kim, H. J., et al. (2017) · Medicine · doi:10.1097/md.0000000000005702 · Cited by 27
Catts, Z. A., Baig, M. K., Milewski, B., Keywan, C., Guarino, M. J., & Petrelli, N. J. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-015-5026-x · Cited by 26
Risk of pancreatic cancer in patients with systemic lupus erythematosus: a meta-analysis
Seo, M. S., Yeo, J., Hwang, I. C., & Shim, J. (2019) · Clinical Rheumatology · doi:10.1007/s10067-019-04660-9 · Cited by 25
Multidisciplinary diagnostic and therapeutic approaches to pancreatic cystic lesions
Buscaglia, J. M., Clores, M. J., & Thosani, A. J. (2014) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s43098 · Cited by 24
Management of pancreatic cysts
Law, J. K., Hruban, R. H., & Lennon, A. M. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e328363e3b3 · Cited by 12
Pancreatic Cancer and a Novel MSH2 Germline Alteration
Lindor, N. M., Petersen, G. M., Spurdle, A. B., Thompson, B. A., Goldgar, D. E., & Thibodeau, S. N. (2011) · Pancreas · doi:10.1097/mpa.0b013e318220c217 · Cited by 12
Cited by
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment
Wood, L. D., Canto, M. I., Jaffee, E. M., & Simeone, D. M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.03.056 · Cited by 865
Stoffel, E. M., Brand, R. E., & Goggins, M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.012 · Cited by 512
Therapeutic developments in pancreatic cancer
Hu, Z. I., & O’Reilly, E. M. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00840-w · Cited by 413
Ghaneh, P., Palmer, D., Cicconi, S., Jackson, R., Halloran, C. M., Rawcliffe, C., Sripadam, R., Mukherjee, S., Soonawalla, Z., Wadsley, J., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00348-x · Cited by 337
The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival
Dbouk, M., Katona, B. W., Brand, R. E., Chak, A., Syngal, S., Farrell, J. J., Kastrinos, F., Stoffel, E. M., Blackford, A. L., Rustgi, A. K., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00298 · Cited by 247
“Since 2018,National Comprehensive CancerNetwork guidelines have recommended individuals with PDAC and their first-degree relatives be offered susceptibility gene testing.(21,22) Among the 26 PDACs, 19 were detected during surveillance, 57.”
Background
Metadata
- Authors
- Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Del Chiaro, M., Dillhoff, M., Donahue, T. R., Dotan, E., Ferrone, C. R., Fountzilas, C., Hardacre, J., Hawkins, W. G., Klute, K., Ko, A. H., Kunstman, J. W., LoConte, N., Lowy, A. M., Moravek, C., Nakakura, E. K., Narang, A. K., Obando, J., Polanco, P. M., Reddy, S., Reyngold, M., Scaife, C., Shen, J., Vollmer, C., Wolff, R. A., Wolpin, B. M., Lynn, B., & George, G. V.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2021-04
- Volume
- 19
- Issue
- 4
- Pages
- 439-457
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W3153075376
- Cited by
- 1,304
- References
- 204
- FWCI
- 69.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.